{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:04:49Z","timestamp":1790697889901,"version":"4.1.0"},"reference-count":21,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T00:00:00Z","timestamp":1754179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of VitreoRetinal Diseases"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To describe the first use of the bispecific monoclonal antibody faricimab for sarcoid uveitis with refractory cystoid macular edema (CME).\n                    <jats:bold>Methods:<\/jats:bold>\n                    A single case was evaluated.\n                    <jats:bold>Results:<\/jats:bold>\n                    An 82-year-old woman presented with blurred vision and signs of sarcoid uveitis bilaterally, including swollen optic discs with disc nodules, CME with chorioretinal peripheral lesions in the right eye and segmental periphlebitis in the left eye. Treatment with intravitreal faricimab was initiated after systemic and topical prednisolone and oral ibuprofen failed. Significant improvement in the patient\u2019s best-corrected visual acuity and central subfield thickness was seen after 2 faricimab injections. Optical coherence tomography showed resolution of the intraretinal cyst and CME. Color fundus photography also showed improvement in the optic disc swelling and resolution of the retinal macroaneurysm.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Faricimab can be a promising treatment for refractory CME in patients with sarcoid uveitis.\n                  <\/jats:p>","DOI":"10.1177\/24741264251358628","type":"journal-article","created":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T09:57:16Z","timestamp":1754215036000},"page":"712-716","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Faricimab as Treatment for Sarcoid Uveitis With Refractory Cystoid Macular Edema"],"prefix":"10.1177","volume":"9","author":[{"given":"Ting-Han","family":"Lin","sequence":"first","affiliation":[{"name":"China Medical University Hospital, China Medical University, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-Yi","family":"Lin","sequence":"additional","affiliation":[{"name":"National Taichung University of Science and Technology, Taichung City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsun","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0519-2446","authenticated-orcid":false,"given":"Po-Chen","family":"Tseng","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Taipei City Hospital, Renai Branch, Taipei, Taiwan"},{"name":"Department of Optometry, University of Kang-Ning, Taipei, Taiwan"},{"name":"Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,3]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccm.2015.08.009"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.03.003"},{"key":"e_1_3_2_4_2","volume-title":"Kanski\u2019s Clinical Ophthalmology: A Systematic Approach","author":"Bowling B","year":"2016","unstructured":"Bowling B, Kanski JJ. Kanski\u2019s Clinical Ophthalmology: A Systematic Approach. Elsevier; 2016."},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-313356"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9123894"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.84.1.110"},{"issue":"14","key":"e_1_3_2_8_2","first-page":"2728","article-title":"Causes of visual loss in uveitis","volume":"52","author":"Kabasele PM","year":"2011","unstructured":"Kabasele PM, Taylor SR, Lightman SL. Causes of visual loss in uveitis. Invest Ophthalmol Vis Sci. 2011;52(14):2728-2728.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_9_2","volume-title":"StatPearls","author":"Sood G","year":"2023","unstructured":"Sood G, Patel BC. Uveitic macular edema. In: StatPearls. StatPearls Publishing; 2023."},{"issue":"7","key":"e_1_3_2_10_2","article-title":"Treatment outcomes of anti-VEGF agents for non-infectious uveitic macula edema","volume":"63","author":"Oyeniran E","year":"2022","unstructured":"Oyeniran E, Bhandari S, Sen HN, Kodati S. Treatment outcomes of anti-VEGF agents for non-infectious uveitic macula edema. Invest Ophthalmol Vis Sci. 2022;63(7):3210\u2013A0436.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S166092"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1879791"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-01377-x"},{"issue":"13","key":"e_1_3_2_14_2","first-page":"2354","article-title":"Anti -VEGF\/Ang2 bi-specific antibody ameliorates endotoxin-induced uveitis in mice","volume":"55","author":"Iwata D","year":"2014","unstructured":"Iwata D, Lundh von Leithner P, Ng YSE, Hartmann G, Shima DT. Anti -VEGF\/Ang2 bi-specific antibody ameliorates endotoxin-induced uveitis in mice. Invest Ophthalmol Vis Sci. 2014;55(13):2354-2354.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201505889"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.11.028"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S40268"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.177279"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21249544"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2017.02.023"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294745"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2023.2293925"}],"container-title":["Journal of VitreoRetinal Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251358628","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/24741264251358628","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/24741264251358628","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:25:56Z","timestamp":1790695556000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/24741264251358628"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,3]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1177\/24741264251358628"],"URL":"https:\/\/doi.org\/10.1177\/24741264251358628","relation":{},"ISSN":["2474-1264","2474-1272"],"issn-type":[{"value":"2474-1264","type":"print"},{"value":"2474-1272","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,3]]}}}